

Cristian Rodriguez-Aguayo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6166772/cristian-rodriguez-aguayo-publications-by-year.pdf>

Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

111 papers	6,065 citations	48 h-index	76 g-index
119 ext. papers	7,266 ext. citations	10.8 avg, IF	5.09 L-index

#	Paper	IF	Citations
111	Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer.. <i>Pharmacological Reports</i> , 2022 , 1	3.9	1
110	RNA delivery for cancer gene therapy 2022 , 375-424		
109	RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. <i>Cell Reports</i> , 2021 , 37, 109934	10.6	4
108	Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity. <i>Journal of the American Chemical Society</i> , 2021 , 143, 7655-7670	16.4	8
107	Explainable Artificial Intelligence Reveals Novel Insight into Tumor Microenvironment Conditions Linked with Better Prognosis in Patients with Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
106	The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. <i>Oncogene</i> , 2021 , 40, 384-395	9.2	7
105	Role of tissue-factor bearing extracellular vesicles released from ovarian cancer cells in platelet aggregation in vitro and venous thrombosis in mice. <i>Thrombosis Update</i> , 2021 , 2, 100020	0.9	4
104	Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. <i>Methods in Molecular Biology</i> , 2021 , 2372, 157-168	1.4	
103	PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
102	Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 2352-2361	6.1	0
101	NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1727-1735	6.1	2
100	Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. <i>Gut</i> , 2020 , 69, 1818-1831	19.2	49
99	Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
98	Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. <i>RNA Biology</i> , 2020 , 17, 1523-1534	4.8	9
97	Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology. <i>Cancers</i> , 2020 , 12,	6.6	9
96	Extraction of Alkaloids Using Ultrasound from Pulp and By-Products of Soursop Fruit (<i>Annona muricata</i> L.). <i>Applied Sciences (Switzerland)</i> , 2020 , 10, 4869	2.6	7
95	Back to the Future: Rethinking the Great Potential of lncRNA for Optimizing Chemotherapeutic Response in Ovarian Cancer. <i>Cancers</i> , 2020 , 12,	6.6	6

94	PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. <i>EBioMedicine</i> , 2019 , 40, 290-304	8.8	20
93	GnRH-R-Targeted Lytic Peptide Sensitizes Wild-type Ovarian Cancer to PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 969-979	6.1	9
92	Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. <i>Oncogene</i> , 2019 , 38, 6095-6108	10.8	29
91	A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. <i>Journal of Clinical Investigation</i> , 2019 , 129, 5343-5356	15.9	25
90	miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2019 , 29, 4389-4406.e10	10.6	36
89	Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 421-436	6.1	7
88	The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. <i>Molecular Therapy - Nucleic Acids</i> , 2019 , 14, 301-317	10.7	17
87	/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 162-172	6.1	11
86	ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. <i>Cell Reports</i> , 2018 , 23, 823-837	10.6	22
85	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. <i>Cancer Research</i> , 2018 , 78, 3233-3242	10.1	46
84	Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. <i>Nature Communications</i> , 2018 , 9, 476	17.4	31
83	A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. <i>Nature Communications</i> , 2018 , 9, 461	17.4	39
82	HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. <i>Stem Cell Reports</i> , 2018 , 10, 212-227	8	32
81	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA induce myeloid malignancies via unique SNP-specific RNA mutations. <i>Genome Research</i> , 2018 , 28, 432-447	9.7	45
80	Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). <i>Oncogene</i> , 2018 , 37, 722-731	9.2	23
79	FABP4 as a key determinant of metastatic potential of ovarian cancer. <i>Nature Communications</i> , 2018 , 9, 2923	17.4	82
78	Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. <i>Clinical Cancer Research</i> , 2018 , 24, 5072-5084	12.9	19
77	Activating Transcription Factor 4 Modulates TGF β -Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. <i>Clinical Cancer Research</i> , 2018 , 24, 5697-5709	12.9	26

76	Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. <i>Clinical Cancer Research</i> , 2018 , 24, 4225-4241	12.9	48
75	MYC Targeted Long Noncoding RNA DANCER Promotes Cancer in Part by Reducing p21 Levels. <i>Cancer Research</i> , 2018 , 78, 64-74	10.1	76
74	RNA interference-based therapy and its delivery systems. <i>Cancer and Metastasis Reviews</i> , 2018 , 37, 107-124	12.4	120
73	Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. <i>EBioMedicine</i> , 2018 , 38, 100-112	8.8	100
72	Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 966-976	6.1	31
71	Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1114-1123	6.1	61
70	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. <i>Clinical Cancer Research</i> , 2017 , 23, 2891-2904	12.9	90
69	Role of Platelet-Derived Tgf β in the Progression of Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5611-5621	12.9	39
68	miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. <i>Scientific Reports</i> , 2017 , 7, 3614	4.9	18
67	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. <i>Genome Biology</i> , 2017 , 18, 98	18.3	75
66	Nutritional characteristics and bioactive compound content of guava purees and their effect on biochemical markers of hyperglycemic and hypercholesterolemic rats. <i>Journal of Functional Foods</i> , 2017 , 35, 447-457	5.1	10
65	Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. <i>Oncotarget</i> , 2017 , 8, 20145-20164	3.3	43
64	Regulation of hnRNPA1 by microRNAs controls the miR-18a- axis in chemotherapy-resistant ovarian cancer. <i>Cell Discovery</i> , 2017 , 3, 17029	22.3	20
63	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. <i>Nature Communications</i> , 2017 , 8, 310	17.4	112
62	Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. <i>Molecular Therapy - Nucleic Acids</i> , 2017 , 9, 251-262	10.7	44
61	Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. <i>Oncogene</i> , 2017 , 36, 1339-1350	9.2	35
60	Exosomes: From Garbage Bins to Promising Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	253
59	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. <i>JCI Insight</i> , 2017 , 2,	9.9	20

58	Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 27380-27392	3.3	9
57	Chitosan Nanoparticles for miRNA Delivery. <i>Methods in Molecular Biology</i> , 2017 , 1632, 219-230	1.4	7
56	Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. <i>Oncogene</i> , 2016 , 35, 2390-7	9.2	51
55	Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. <i>Cancer Cell</i> , 2016 , 30, 273-289	24.3	92
54	Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. <i>Cell Reports</i> , 2016 , 17, 1621-1631	16.1	17
53	Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. <i>Cancer Research</i> , 2016 , 76, 7194-7207	10.1	92
52	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. <i>Nature Communications</i> , 2016 , 7, 11169	17.4	83
51	Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. <i>Cancer Cell</i> , 2016 , 29, 874-888	24.3	29
50	Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. <i>Oncogene</i> , 2016 , 35, 691-701	9.2	30
49	Role of Increased n-acetylaspartate Levels in Cancer. <i>Journal of the National Cancer Institute</i> , 2016 , 108, djv426	9.7	32
48	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. <i>Molecular Cell</i> , 2016 , 61, 520-534	17.6	101
47	Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. <i>Oncogene</i> , 2016 , 35, 4312-20	9.2	70
46	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1713-24	12.9	47
45	Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. <i>JCI Insight</i> , 2016 , 1, e87754	9.9	10
44	Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 15093-15104	3.5	49
43	Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. <i>Hepatology</i> , 2016 , 63, 864-79	11.2	63
42	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. <i>Hepatology</i> , 2016 , 63, 159-72	11.2	80
41	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. <i>Cell Reports</i> , 2016 , 15, 1493-1504	10.6	56

40	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2127-37	12.9	49
39	The ZNF304-integrin axis protects against anoikis in cancer. <i>Nature Communications</i> , 2015 , 6, 7351	17.4	37
38	TP53 loss creates therapeutic vulnerability in colorectal cancer. <i>Nature</i> , 2015 , 520, 697-701	50.4	154
37	Erythropoietin Stimulates Tumor Growth via EphB4. <i>Cancer Cell</i> , 2015 , 28, 610-622	24.3	60
36	MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. <i>Journal of Pathology</i> , 2015 , 235, 25-36	9.4	81
35	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. <i>Npj Systems Biology and Applications</i> , 2015 , 1, 15001	5	3
34	A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. <i>Molecular Systems Biology</i> , 2015 , 11, 842	12.2	9
33	Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	80
32	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. <i>Cell Reports</i> , 2015 , 13, 2395-2402	10.6	75
31	CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. <i>PLoS ONE</i> , 2015 , 10, e0131833	3.7	18
30	Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. <i>Oncotarget</i> , 2015 , 6, 4266-73	3.3	56
29	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. <i>Nature Communications</i> , 2014 , 5, 5202	17.4	130
28	2TOMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. <i>Nature Communications</i> , 2014 , 5, 3459	17.4	81
27	Therapeutic silencing of KRAS using systemically delivered siRNAs. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2876-85	6.1	59
26	Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2583-94	6.1	21
25	Hematogenous metastasis of ovarian cancer: rethinking mode of spread. <i>Cancer Cell</i> , 2014 , 26, 77-91	24.3	203
24	Autocrine effects of tumor-derived complement. <i>Cell Reports</i> , 2014 , 6, 1085-1095	10.6	118
23	Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. <i>Molecular Systems Biology</i> , 2014 , 10, 728	12.2	178

22	Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. <i>Cancer Cell</i> , 2014 , 26, 863-879	24.3	34
21	miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. <i>Nature Communications</i> , 2014 , 5, 5671	17.4	125
20	Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. <i>Journal of Liposome Research</i> , 2014 , 24, 182-90	6.1	17
19	EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. <i>Carcinogenesis</i> , 2014 , 35, 1100-9	4.6	28
18	Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. <i>Cancer Discovery</i> , 2013 , 3, 1302-15	24.4	123
17	Tumour angiogenesis regulation by the miR-200 family. <i>Nature Communications</i> , 2013 , 4, 2427	17.4	295
16	Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. <i>Cancer Cell</i> , 2013 , 23, 186-99	24.3	305
15	Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. <i>Cancer Cell</i> , 2013 , 23, 705	24.3	6
14	Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. <i>Cancer Letters</i> , 2013 , 330, 123-9	9.9	20
13	Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. <i>Hepatology</i> , 2013 , 58, 182-91	11.2	64
12	RNAi in Cancer Therapy 2013 , 271-307		
11	Src activation by Adrenoreceptors is a key switch for tumour metastasis. <i>Nature Communications</i> , 2013 , 4, 1403	17.4	141
10	Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. <i>Clinical Cancer Research</i> , 2013 , 19, 1806-15	12.9	92
9	Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. <i>PLoS ONE</i> , 2013 , 8, e79167	3.7	156
8	ATP11B mediates platinum resistance in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2119-30	13.9	44
7	ATP11B mediates platinum resistance in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2013 , 123, 5411-5417	15.1	78
6	Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. <i>Breast Cancer Research</i> , 2012 , 14, R108	8.3	54
5	FOX11 mediates Dox resistance in breast cancer by enhancing DNA repair. <i>Carcinogenesis</i> , 2012 , 33, 1843-53	4.6	82

4	Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. <i>PLoS ONE</i> , 2011 , 6, e17918	3.7	65
3	Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 3716-26	12.9	55
2	Neuropilin-2 mediated Eatenin signaling and survival in human gastro-intestinal cancer cell lines. <i>PLoS ONE</i> , 2011 , 6, e23208	3.7	27
1	c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 184-94	12.9	49